AstraZeneca closes India R&D shop

Share this article:

AstraZeneca is laying off 168 pharmaceutical employees at the Avishkar R&D site in Bangalore, India. The company said in a statement that the move is in line with its shift to focus on three core areas—oncology; cardiovascular and metabolic; and respiratory, inflammation and autoimmunity.

The Avishkar operation was focused on conditions including TB, malaria and neglected tropical diseases. AstraZeneca will continue to develop Phase-II TB medication AZD5847. The company said it will continue to make its compound library available to open-innovation partnerships.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.